Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer.
Shijia ZhangDaniel F PeaseAmit A KulkarniManoj KumarRyan M ShanleyBeibei XuShilvi P JoshiManish R PatelPublished in: Clinical Medicine Insights. Oncology (2021)
The clinical benefit of ICIs appears to persist in a real-world population of relatively older age, including those with poor PS and pre-existing autoimmune diseases. ECOG PS of 0 to 1 and BMI ⩾ 25 kg/m2 were independently associated with improved OS.